A preliminary clinical study of acatinib mesylate combined with docetaxel and fluorouracil in the treatment of advanced gastric cancer or gastro esophageal junction adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 12 Apr 2018 New trial record